Updates are available Correction dated 2018-12-19
Click to view Correction: https://doi.org/10.1038/s41591-018-0333-y
-
Authors
Chen, Jiahao
Kao, Yun-Ruei
Sun, Daqian
Todorova, Tihomira I.
Reynolds, David
Narayanagari, Swathi-Rao
Montagna, Cristina
Will, Britta
Verma, Amit https://orcid.org/0000-0001-7592-7693
Steidl, Ulrich https://orcid.org/0000-0002-9458-1795
- License Information
-
More Information
Article History
Received: 7 August 2018
Accepted: 23 October 2018
First Online: 3 December 2018
Change Date: 19 December 2018
Change Type: Correction
Change Details: In the version of this article originally published, Ulrich Steidl’s name was listed as “and Ulrich Steidl.” His name has been updated to “Ulrich Steidl.” The error has been fixed in the print, PDF and HTML versions of this article.
Competing interests
: U.S. has received research funding from GlaxoSmithKline, Bayer Healthcare, Aileron Therapeutics, and Novartis; has received compensation for consultancy services and for serving on scientific advisory boards from GlaxoSmithKline, Bayer Healthcare, Celgene, Aileron Therapeutics, Stelexis Therapeutics, and Pieris Pharmaceuticals; and has equity ownership in and is serving on the board of directors of Stelexis Therapeutics. A.V. has received research funding from GlaxoSmithKline, Incyte, MedPacto, Novartis, and Eli Lilly and Company, has received compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene, and has equity ownership in Stelexis Therapeutics. B.W. has received research support from Novartis Pharmaceuticals.
